Targeted drugs can replace chemotherapy to some extent, especially until the targeted drugs lose their effectiveness or are not resistant to chemotherapy. Take lung cancer as an example, if there is a gene mutation, such as EGFR gene mutation or ALK gene mutation, the efficacy of using drugs targeting EGFR gene mutation, such as gefitinib and erlotinib, is better than that of cisplatin-based chemotherapy drugs, and similarly crizotinib represents a better targeted drug than chemotherapy drugs, which is a conclusion that has been proven by many evidence-based medical studies. However, if resistance to targeted drugs occurs and there is no new generation of targeted drugs, chemotherapy is an essential treatment, especially for multiple metastases, which is a unique position.